<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00338897</url>
  </required_header>
  <id_info>
    <org_study_id>DRI5664</org_study_id>
    <secondary_id>EudraCT : 2006-000152-41</secondary_id>
    <nct_id>NCT00338897</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study in Elective Total Hip Replacement Surgery</brief_title>
  <acronym>DRIVE</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group, Dose Ranging Study of Subcutaneous SR123781A With an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objective is to:

        -  demonstrate the efficacy of SR123781A in the prevention of venous thromboembolism (VTE)
           by the demonstration of a dose-response in patients undergoing total hip replacement
           surgery.

      The secondary objectives are to:

        -  evaluate the safety of SR123781A in the prevention of VTE after elective total hip
           replacement surgery; and

        -  to assess the SR123781A pharmacokinetic profile in patients undergoing elective total
           hip replacement surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint is a composite of total venous thromboembolic events (VTE) including VTE related deaths during the treatment period.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy endpoints will include all deep vein thrombosis events [DVTs] (proximal or distal) and all symptomatic VTEs (pulmonary embolisms [PEs] or DVTs)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The main safety criterion is the incidence of major bleedings occurring from the first study drug administration to 3 calendar days after the last study drug administration.</measure>
  </secondary_outcome>
  <enrollment type="Actual">1090</enrollment>
  <condition>Venous Thromboembolism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR123781A</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled to undergo elective total hip replacement surgery or a revision of
             at least one component of a total hip replacement performed &gt; 6 months prior to study
             entry

        Exclusion Criteria:

          -  Pregnant or nursing women, or women of childbearing potential who are not using an
             effective contraceptive method and who do not have a negative pregnancy test performed
             immediately before randomization

          -  Known progressive malignant disease

          -  Ischemic stroke in the last 3 months

          -  Myocardial infarction (MI) in the last 3 months

          -  Any major orthopedic surgery in the 3 months prior to study start

          -  Clinical signs or symptoms of DVT or PE within the last 12 months or symptoms of post
             phlebitic syndrome (these conditions may confound DVT/PE assessments)

          -  Treatment with other antithrombotic agents within 7 days prior to surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Rud Lassen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hoersholm Hospital, Spine Clinic, Usserod Kongevej 102, DK-2970 Hoerholm, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>San Isidro</city>
        <state>Buenos Aires</state>
        <zip>1642</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Sofia</city>
        <zip>1715</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Providencia</city>
        <state>Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Santafe de Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Praha</city>
        <zip>160 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Denmark</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Mexico</city>
        <zip>04000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bucuresti</city>
        <zip>70334</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Moscow</city>
        <zip>101000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Istanbul</city>
        <zip>34394</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Croatia</country>
  </removed_countries>
  <link>
    <url>http://www.sanofi-aventis.com</url>
  </link>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2006</study_first_submitted>
  <study_first_submitted_qc>June 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2006</study_first_posted>
  <last_update_submitted>December 9, 2008</last_update_submitted>
  <last_update_submitted_qc>December 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Venous Thromboembolism</keyword>
  <keyword>Prevention</keyword>
  <keyword>Arthroplasty</keyword>
  <keyword>Replacement</keyword>
  <keyword>Hip</keyword>
  <keyword>orthopedic surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

